WEBULL
News
ZBIO
25.82
+10.96%
2.55
Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
Benzinga · 2d ago
Zenas BioPharma: Advancing Autoimmune Pipeline and Obexelimab’s Differentiated MS Profile Support Buy Rating and $44 Target
TipRanks · 2d ago
Zenas Biopharma Highlights Results From Phase 2 MoonStone Trial Of Obexelimab In RMS In Late-Breaking Oral Presentation At ACTRIMS Forum 2026
Benzinga · 3d ago
Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions
Reuters · 3d ago
ZENAS BIOPHARMA ANNOUNCES LATE-BREAKING PLATFORM PRESENTATION OF RESULTS FROM PHASE 2 MOONSTONE TRIAL OF OBEXELIMAB IN RELAPSING MULTIPLE SCLEROSIS AT ACTRIMS FORUM 2026
Reuters · 3d ago
Weekly Report: what happened at ZBIO last week (0202-0206)?
Weekly Report · 3d ago
Does Zenas BioPharma (ZBIO) CEO’s Million‑Dollar Share Buy Reframe Management Credibility After Recent Setbacks?
Simply Wall St · 3d ago
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Phase 3 INDIGO Data And CEO Share Purchase
Simply Wall St · 6d ago
Zenas Bio rises after over $1M stock purchase by CEO
Seeking Alpha · 02/04 15:16
Zenas BioPharma to Present at Guggenheim Emerging Outlook: Biotech Summit
Reuters · 02/04 12:05
A Big Boss Bet on Zenas BioPharma’s Future
TipRanks · 02/04 02:01
Zenas Biopharma CEO Leon O. Moulder Jr. Reports Acquisition of Common Shares
Reuters · 02/03 21:31
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 02/02 21:05
Weekly Report: what happened at ZBIO last week (0126-0130)?
Weekly Report · 02/02 10:27
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Zenas BioPharma, Inc. (ZBIO)
TipRanks · 01/30 12:51
Weekly Report: what happened at ZBIO last week (0119-0123)?
Weekly Report · 01/26 10:27
Weekly Report: what happened at ZBIO last week (0112-0116)?
Weekly Report · 01/19 10:34
Zenas BioPharma Grants Stock Options to New Employee Under Inducement Plan
Reuters · 01/16 21:15
ZENAS BIOPHARMA ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 01/16 21:15
More
Webull provides a variety of real-time ZBIO stock news. You can receive the latest news about Zenas BioPharma Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.